Carbylan Therapeutics, Inc. is a clinical-stage specialty pharmaceutical company focused on the development and commercialization of combination therapies. It focuses on the development of Hydros-TA, its intra-articular (IA) injectable product candidate to treat pain associated with osteoarthritis (OA) of the knee. Hydros-TA delivers both rapid pain relief with a low dose corticosteroid triamcinolone acetonide (TA) and sustained pain relief from its hyaluronic acid viscosupplement. Its Hydros-TA is a combination IA product, designed to provide both rapid and sustained pain relief with a single six milliliters intra-articular injection consists of over 52 milligrams of bacterially derived HA and over 10 milligrams of TA. Its first Phase III clinical trial of Hydros-TA, COR1.1, was a multi-center, international, randomized, double-blind, three-arm trial. Its Phase IIb clinical trial of Hydros-TA, COR1.0, was a multicenter, randomized, double-blind feasibility study.